```text
bjp_cannabis_synergy_review.txt

THC primary focus of cannabis research since 1964 (Mechoulam). Cannabidiol (CBD) synergistic contributions to pharmacology & analgesia demonstrated.  Other phytocannabinoids (THCV, CBG, CBC) have therapeutic effects.  Plant breeding yields high-titre chemotypes.  Cannabis terpenoids (limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol, phytol) explored.  Terpenoids share precursor with phytocannabinoids; GRAS status (FDA).  Potent; affect behavior at ng·mL⁻¹ serum levels. Unique therapeutic effects; contribute to entourage effects. Phytocannabinoid-terpenoid interactions may synergize in treating pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal/bacterial infections (MRSA).  Non-cannabinoid components as potential THC antidotes; increase therapeutic index. Methods for investigating entourage effects proposed. Synergy increases likelihood of new therapeutics.

Phytocannabinoid & terpenoid synthesis in glandular trichomes (Figure 1), concentrated in unfertilized female flowers (Potter). Geranyl pyrophosphate precursor (deoxyxylulose pathway; Fellermeier).  Forms phytocannabinoids (olivetolic/divarinic acid coupling; de Meijer) & terpenoids (Figure 2). Acid phytocannabinoids decarboxylated by heat (Table 1).  Geranyl pyrophosphate forms limonene & monoterpenoids; farnesyl pyrophosphate forms sesquiterpenoids (co-localizes with TRPV1; Bradshaw; GPR92 ligand; Oh).

Cannabis synergy mechanisms: (i) multi-target effects; (ii) pharmacokinetic effects (solubility/bioavailability); (iii) agent interactions (bacterial resistance); (iv) adverse event modulation (Wagner).  Cannabis extracts show effects 2–4x greater than THC (Carlini); unidentified antagonists/synergists (Fairbairn).  Anticonvulsant activity beyond cannabinoid fraction (Wilkinson); THC/CBD extract effects differ from pure compounds (Ryan).  Contrasting views exist: no differences between pure THC & herbal cannabis (Wachtel); pure THC accounts for all effects in mice (Varvel); no subjective differences with varying CBD/CBC (Ilan).  Explanations: low CBN/CBD in Wachtel/Ilan studies; higher terpenoid yields in street cannabis (Bloor). Black market cannabis is high-THC (Potter, King, Mehmedic).  Biochemical/pharmacological/phenomenological distinctions likely related to terpenoid content/ratios.

Phytocannabinoids beyond THC: THC maximizes with light (Potter); CBG/CBC mildly antifungal (ElSohly); trichome stickiness traps insects (Potter); THCA & CBCA produce necrosis (Morimoto, Shoyama).  Over 100 phytocannabinoids identified (Brenneisen, Mehmedic); pharmacology reviewed (Pertwee, Izzo, De Petrocellis).

THC: CB1/CB2 partial agonist; psychoactive, analgesic, muscle relaxant, antispasmodic (Pacher); bronchodilator (Williams); neuroprotective antioxidant (Hampson); antipruritic (Neff); anti-inflammatory (Evans).  Avoids COX-1/COX-2 pitfalls (Stott).

CBD: most common in hemp; versatile (Pertwee, Mechoulam); CB1 antagonist with THC; modulates THC adverse events (Nicholson, Murillo-Rodriguez, Russo); analgesic (Costa); neuroprotective antioxidant (Hampson); TRPV1 agonist (Bisogno); AEA uptake inhibitor; GPR55/GPR18 antagonist (McHugh); anticonvulsant (Carlini, Jones); anti-nausea (Parker); cytotoxic in breast cancer (Ligresti); cyto-preservative (Parolaro); TNF-α antagonist (Malfait); enhances adenosine A2A signaling (Carrier); prevents prion accumulation (Dirikoc); anti-hyperalgesia (Comelli); effective against MRSA (Appendino); 5-HT1A agonist (Russo); anti-anxiety (Resstel, Soares); reduces stroke risk (Mishima); anti-nausea (Rock); improves cognition (Magen); antidepressant (Zanelati). Inhibits sebocytes (Biro). Critical in nabiximols for cancer pain (Johnson).

CBC: inactive on adenylate cyclase (Howlett); mouse cannabinoid tetrad activity (Delong); anti-inflammatory (Wirth); analgesic (Davis); reduces THC intoxication (Hatoum); antibiotic/antifungal (ElSohly); cytotoxic in cancer (Ligresti); antidepressant (Deyo); TRPA1 stimulator (De Petrocellis); AEA uptake inhibitor (De Petrocellis).

CBG: weak CB1/CB2 partial agonist (Gauson); GABA uptake inhibitor (Banerjee); analgesic/anti-erythemic (Evans); antifungal (ElSohly); cytotoxic (Baek, Ligresti); antidepressant (Musty); anti-hypertensive (Maor); inhibits keratinocytes (Wilkinson); TRPM8 antagonist (De Petrocellis);  AEA uptake inhibitor (De Petrocellis); effective against MRSA (Appendino); α-2 adrenoreceptor agonist (Formukong, Cascio); 5-HT1A antagonist (Cascio).  Breeding yields 100% CBG chemotypes (de Meijer).

THCV: propyl THC analogue; modulates THC intoxication (Gill, Hollister); CB1 antagonist/agonist (Thomas, Pertwee); weight loss in mice (Cawthorne, Riedel); anticonvulsant (Hill); suppresses hyperalgesia/inflammation (Bolognini).

CBDV: propyl CBD analogue; inhibits diacylglycerol lipase (De Petrocellis); anticonvulsant (Jones).

CBN: THC by-product; lower CB1/CB2 affinity (Rhee); sedative with THC (Musty); anticonvulsant (Turner); anti-inflammatory (Evans); effective against MRSA (Appendino); TRPV2 agonist (Qin); inhibits keratinocytes (Wilkinson); inhibits breast cancer resistance protein (Holland).

Cannabis terpenoids: aroma; over 200 identified (Hendriks, Malingre, Ross, Brenneisen); few studies on pharmacology (McPartland).  Yield <1% (Potter). Monoterpenes (limonene, myrcene, pinene) predominate; sesquiterpenoids (caryophyllene) in extracts (Guy).  Phytochemical polymorphism (Franz).  Terpenoid mixtures determine viscosity; sticky exudations trap insects (McPartland).  Production increases with light; decreases with soil fertility (Langenheim).  EO composition genetically determined (Franz).  Vegetative propagation yields consistency (Potter, Fischedick). 28 EOs in European Pharmacopoeia (Pauli).  Lipophilic; interact with cell membranes, ion channels, receptors, second messenger systems, enzymes (Bowles, Buchbauer).  GRAS status; non-sensitizing (Tisserand, Adams).

Terpenoid relevance: concentrations >0.05% of pharmacological interest (Adams). Animal studies show effects at low serum concentrations (Buchbauer).  Comparable to THC levels in humans (Russo, Huestis). Limonene highly bioavailable (Falk-Filipsson); pinene rapid metabolism/redistribution (Falk).  Ingestion/percutaneous absorption documented (Jäger).  EO mixtures increase estradiol permeation (Monti). Gamma-irradiation reduces linalool (Fan).

D-limonene: widespread; anxiolytic (Carvalho-Freitas, Komori, Komiya); apoptosis in breast cancer (Vigushin); anti-stress (Fukumoto); treats gastro-oesophageal reflux (Harris); effective against dermatophytes (Sanguinetti, Singh); radical scavenging (Choi); highly bioavailable & rapidly metabolized (Falk-Filipsson); low toxicity (Von Burg).

β-myrcene: anti-inflammatory (Lorenzetti); blocks hepatic carcinogenesis (De Oliveira); analgesic (Rao); sedative (Bisset, do Vale).

α-pinene: widespread; anti-inflammatory (Gil); bronchodilator (Falk); antibiotic (Nissen); acetylcholinesterase inhibitor (Perry, Miyazawa); CB2 ligand precursor (Hanus).

D-linalool: anxiolytic (Russo); sedative (Buchbauer, Jirovetz); local anesthetic (Re, Ghelardini); analgesic (Peana, Batista); anticonvulsant (Elisabetsky, Ismail).

β-caryophyllene: most common sesquiterpenoid; attracts insect predators (Langenheim); anti-inflammatory (Basile, Ozturk); gastric cytoprotective (Tambe); anti-malarial (Campbell); CB2 full agonist (Gertsch); anti-inflammatory/analgesic (Gertsch).

Nerolidol: sedative (Binet); reduced colon adenomas (Wattenberg); enhances skin penetration (Cornwell); antimalarial (Lopes, Rodrigues Goulart); anti-leishmanial (Arruda); non-toxic/non-sensitizing (Lapczynski).

Caryophyllene oxide: insecticidal/anti-feedant (Bettarini); antifungal (Langenheim, Yang); anti-platelet aggregation (Lin).  Used for cannabis detection (Stahl).

Phytol: diterpene; prevents vitamin A teratogenesis (Arnhold); increases GABA (Bang).

Phytocannabinoid-terpenoid synergy: Acne: AEA simulates/induces lipid production/apoptosis in sebocytes (Dobrosi); CBD inhibits lipid synthesis/induces apoptosis (Biro); citrus EOs (limonene) inhibit P. acnes (Kim); linalool inhibits P. acnes (Kim); pinene suppresses P. acnes/Staph (Raman).  CBD-predominant extracts may be a novel acne therapy.

MRSA: CBD/CBG inhibit MRSA (Appendino); pinene effective against MRSA (Kose, Ozek). CBG-chemotype extracts expressing pinene may be an antiseptic agent.

Psychopharmacological applications:  ECS role in depression/anxiety/psychosis (Hill, Marsicano, Giuffrida); CBD mitigates psychosis risk (Morgan); citrus scent improves depression (Komori); CBD effects on 5-HT1A support anti-anxiety (Russo, Fusar-Poli, Crippa); limonene/linalool may enhance CBD efficacy; THC effective in Alzheimer’s (Volicer, Eubanks); CBD may have primary benefits in Alzheimer's (Iuvone, Esposito); CBD eliminates cognitive/memory deficits (Morgan); limonene/pinene/linalool may extend mood benefits; terpenoids may supplement sleep benefits (Russo); CBD in addiction treatment (Parker, Ren, Borgwardt, Morgan, Crippa); caryophyllene may provide adjunctive support (Rose, Xi).

THC antidotes: CBD modulates THC psychoactivity (Russo); historical antidotes (Al-Razi, ibn Sina, ibn al-Baytar, Christison, Taylor, Ludlow, Calkins, Walton): lemon juice/citrus; Acorus calamus (Lad, McPartland); Pliny: pine nuts/pepper/honey/palm wine (Pliny); Al-Ukbari: pistachio nuts (Lozano);  α-pinene as acetylcholinesterase inhibitor (Miyazawa).

Conclusions: Selective breeding of cannabis chemotypes rich in phytocannabinoids and terpenoids yields complementary pharmacological activities; improves therapeutic index.  Elucidation of biosynthetic pathways needed (Croteau, Gershenzon, Bohlmann, Trapp). High throughput screening needed.  Investigate biochemical targets/mechanisms of action.  Radio-labelling, in silico studies, behavioral assays, fMRI, SPECT studies proposed.  Development of zero-cannabinoid chemotypes facilitates study (de Meijer).  Cannabis may fulfil its promise as a pharmacological treasure trove.
```